<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of extrapulmonary manifestations of sarcoidosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of extrapulmonary manifestations of sarcoidosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of extrapulmonary manifestations of sarcoidosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel A Culver, DO, FCCP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin R Flaherty, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H18587448"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sarcoidosis is a multisystem granulomatous disorder that affects individuals worldwide. The disease was historically thought to present mainly in young or middle-aged adults, but more recent data suggest that it may also occur in the sixth and seventh decades of life, especially in females. Accumulation of nonnecrotizing granulomas and subsequent fibrosis in the lungs and other organs accounts for the clinical manifestations, which may be symptomatic or discovered incidentally when testing is ordered for other purposes. Clinical manifestations vary widely, depending on organ involvement. Some of the most common presentations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral hilar adenopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary reticular and/or nodular opacities</p><p class="bulletIndent1"><span class="glyph">●</span>Skin, joint, or eye lesions</p><p></p><p>This topic provides an overview of extrapulmonary manifestations of sarcoidosis. The initial diagnosis of sarcoidosis and organ-specific clinical manifestations and diagnosis of sarcoidosis involving the heart, neurologic system, gastrointestinal tract, skin, bone, and joints are discussed in more detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4834.html" rel="external">"Neurologic sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4317.html" rel="external">"Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13762.html" rel="external">"Cutaneous manifestations of sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/113435.html" rel="external">"Sarcoidosis of bone"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5583.html" rel="external">"Sarcoid arthropathy"</a>.)</p><p></p><p>The pathogenesis of sarcoidosis and treatment of pulmonary sarcoidosis are also presented elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4365.html" rel="external">"Pathology and pathogenesis of sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4359.html" rel="external">"Treatment of pulmonary sarcoidosis: Initial approach"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4325.html" rel="external">"Treatment of pulmonary sarcoidosis refractory to initial therapy"</a>.)</p><p></p><p class="headingAnchor" id="H611462392"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>At initial presentation, up to 50 percent of patients have extrathoracic manifestations of sarcoidosis based on history and physical examination  (<a class="graphic graphic_table graphicRef76046" href="/z/d/graphic/76046.html" rel="external">table 1</a>) [<a href="#rid1">1-10</a>]. More sensitive testing, such as 18-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET) scan will reveal an even higher proportion of patients with clinically silent extrapulmonary disease. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Common extrapulmonary findings and pathognomonic syndromes'</a>.)</p><p>The most common sites of overt extrapulmonary disease include the skin, eyes, reticuloendothelial system, dysregulation of vitamin D metabolism, exocrine glands, heart, and central nervous system. Approximately 8 percent of patients with sarcoidosis present with disease at extrapulmonary sites without lung involvement; nearly half of these patients have cutaneous disease [<a href="#rid6">6</a>].</p><p>Extrapulmonary manifestations may vary on the basis of sex, age at presentation, and ethnicity  (<a class="graphic graphic_figure graphicRef77449" href="/z/d/graphic/77449.html" rel="external">figure 1</a>) [<a href="#rid1">1,11</a>]. As an example, in one study, women were more likely to have skin or ocular involvement, while men more frequently developed cardiac involvement [<a href="#rid11">11</a>].</p><p>Approximately 5 to 10 percent of patients with sarcoidosis present with Löfgren syndrome, which is defined by acute-onset fever, hilar adenopathy, and variable proportions of erythema nodosum (EN) or bilateral ankle inflammation. Löfgren syndrome is more common in the third and fourth decades of life and is seen more frequently in females than in males [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Common extrapulmonary findings and pathognomonic syndromes'</a> and  <a class="medical medical_review" href="/z/d/html/5612.html" rel="external">"Erythema nodosum"</a> and  <a class="medical medical_review" href="/z/d/html/5583.html" rel="external">"Sarcoid arthropathy", section on 'Acute arthritis and Lofgren syndrome'</a>.)</p><p>Multiple groups have attempted to cluster patients with sarcoidosis based on organ manifestations [<a href="#rid12">12,13</a>]. Other than re-establishing the elements of Löfgren syndrome, however, these analyses have not generated consistent patient groupings.</p><p class="headingAnchor" id="H18586365"><span class="h1">EXTRAPULMONARY DISEASE IN INITIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>A few clinical presentations are so highly specific for sarcoidosis that a biopsy is unlikely to be informative [<a href="#rid14">14</a>]. These presentations include Löfgren syndrome (erythema nodosum [EN], hilar adenopathy, migratory polyarthralgia, and fever) and Heerfordt's syndrome (uveoparotid fever). Occasionally, there may also be sufficient manifestations in multiple organ systems to allow a presumptive clinical diagnosis. Otherwise, the diagnosis of sarcoidosis requires a step-wise approach to identify organs that may be affected and the exclusion of other multisystem granulomatous diseases [<a href="#rid8">8</a>]. A biopsy is generally recommended but can be deferred on an individual basis when the clinical presentation is strongly supportive of sarcoidosis and alternate causes are unlikely. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Initial evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Invasive diagnostic testing'</a>.)</p><p>Baseline testing for occult extrapulmonary disease is recommended as part of the initial work-up of sarcoidosis. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Testing for occult extrapulmonary disease'</a>.)</p><p class="headingAnchor" id="H1181397862"><span class="h1">CLINICAL MANIFESTATIONS BY ORGAN SYSTEM</span></p><p class="headingAnchor" id="H18586371"><span class="h2">Cutaneous</span><span class="headingEndMark"> — </span>Cutaneous involvement is seen in approximately 25 percent of patients with sarcoidosis, and it is often an early finding  (<a class="graphic graphic_table graphicRef76046" href="/z/d/graphic/76046.html" rel="external">table 1</a>). (See <a class="local">'Epidemiology'</a> above.)</p><p>The cutaneous manifestations of sarcoidosis and their management are described in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/13762.html" rel="external">"Cutaneous manifestations of sarcoidosis"</a> and  <a class="medical medical_review" href="/z/d/html/13773.html" rel="external">"Cutaneous sarcoidosis: Management"</a>.) </p><p>The following patterns are among the most common cutaneous manifestations:</p><p class="bulletIndent1"><span class="glyph">●</span>Papular sarcoidosis is a common manifestation that usually involves the alae nares, lips, eyelids, forehead, rear of neck at the hairline, and/or previous trauma sites (eg, scars and tattoos)  (<a class="graphic graphic_picture graphicRef69405 graphicRef56226" href="/z/d/graphic/69405.html" rel="external">picture 1A-B</a> and <a class="graphic graphic_picture graphicRef66626" href="/z/d/graphic/66626.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef91304" href="/z/d/graphic/91304.html" rel="external">picture 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nodular sarcoidosis most frequently involves the face, trunk, and extensor surface of the arms and legs  (<a class="graphic graphic_picture graphicRef50697" href="/z/d/graphic/50697.html" rel="external">picture 4</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plaque-like lesions can occur in chronic sarcoidosis, frequently on the shoulders, arms, back, and buttocks  (<a class="graphic graphic_picture graphicRef52189" href="/z/d/graphic/52189.html" rel="external">picture 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lupus pernio is characterized by violaceous or erythematous indurated papules, plaques, or nodules that are primarily distributed on the nose, cheeks, chin, and ears  (<a class="graphic graphic_picture graphicRef76184 graphicRef63312" href="/z/d/graphic/76184.html" rel="external">picture 6A-B</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythema nodosum (EN) is a panniculitis, characterized by painful nodules that are most common on the anterior surface of the lower extremities  (<a class="graphic graphic_picture graphicRef80056" href="/z/d/graphic/80056.html" rel="external">picture 7</a> and <a class="graphic graphic_picture graphicRef55744" href="/z/d/graphic/55744.html" rel="external">picture 8</a>), which is frequently associated with sarcoidosis. (See  <a class="medical medical_review" href="/z/d/html/5612.html" rel="external">"Erythema nodosum"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subcutaneous sarcoidosis, which is different from EN, is characterized by asymptomatic or mildly tender nodules, usually on the upper extremities. </p><p></p><p>For patients without a confirmed diagnosis of sarcoidosis, a skin biopsy is typically performed to evaluate lesions suggestive of sarcoidosis. As an exception, EN is not biopsied, as it is characterized by panniculitis regardless of underlying disease. (See  <a class="medical medical_review" href="/z/d/html/13762.html" rel="external">"Cutaneous manifestations of sarcoidosis"</a>.)</p><p class="headingAnchor" id="H18586377"><span class="h2">Ocular</span><span class="headingEndMark"> — </span>Ocular involvement occurs in up to 25 percent of patients with sarcoidosis and is the presenting symptom in 5 percent [<a href="#rid15">15</a>]. Ocular manifestations are reported at higher rates in women and in African American and Japanese patient populations [<a href="#rid16">16</a>]. Sarcoidosis can involve the orbit, anterior and posterior segments of the eye, conjunctiva, lacrimal glands, and extraocular muscles [<a href="#rid17">17,18</a>]. For patients with sarcoidosis who do not have ocular symptoms, consensus guidelines from the American Thoracic Society (ATS) suggest a baseline eye examination to screen for ocular sarcoidosis [<a href="#rid14">14</a>]. The retinal manifestations of sarcoidosis and the diagnosis and treatment of uveitis in general are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis", section on 'Systemic inflammatory diseases'</a> and  <a class="medical medical_review" href="/z/d/html/5592.html" rel="external">"Uveitis: Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/8232.html" rel="external">"Retinal vasculitis associated with systemic disorders and infections", section on 'Systemic immune-mediated causes'</a>.)</p><p>In a series of 81 consecutive patients with sarcoidosis seen in an ophthalmology clinic, 40 percent had uveitis, 30 percent had keratoconjunctivitis sicca, and 15 percent had adnexal (eyelid or conjunctival) granulomas [<a href="#rid17">17</a>]. Symptoms included dry eye, blurry vision, photophobia, redness, and pain. </p><p>The combination of anterior uveitis, parotid gland enlargement, facial nerve palsy (due to compression by enlarged parotid gland), and fever (uveoparotid fever) is referred to as Heerfordt's syndrome, an uncommon but pathognomonic presentation of sarcoidosis [<a href="#rid19">19,20</a>]. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Common extrapulmonary findings and pathognomonic syndromes'</a> and  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Pathognomonic presentations'</a>.)</p><p>A diagnosis of ocular sarcoidosis can be difficult and requires input from an ophthalmologist. Patients with a new diagnosis of sarcoidosis should undergo visual acuity, tonometry, slit lamp, and funduscopic testing to assess for ocular involvement [<a href="#rid21">21</a>]. <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">Fluorescein</a> angiography may help in the detection of retinal blood vessel abnormalities, such as retinal vasculitis and retinal periphlebitis. Enlarged lacrimal glands can also be palpated just above and lateral to the orbit  (<a class="graphic graphic_picture graphicRef91304" href="/z/d/graphic/91304.html" rel="external">picture 3</a>) or visualized by everting the upper eyelid  (<a class="graphic graphic_picture graphicRef91303" href="/z/d/graphic/91303.html" rel="external">picture 9</a>). The conjunctivae harbor granulomas [<a href="#rid22">22</a>], and biopsy of the conjunctiva, even in asymptomatic patients, can be helpful to establish the diagnosis. </p><p class="headingAnchor" id="H41251068"><span class="h3">Diagnosis of intraocular sarcoidosis</span><span class="headingEndMark"> — </span>Intraocular manifestations of sarcoidosis are classified as anterior, intermediate, and/or posterior uveitis [<a href="#rid17">17,23</a>]. As ocular involvement may be asymptomatic, all patients with sarcoidosis should undergo ophthalmologic examination. (See  <a class="medical medical_review" href="/z/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis", section on 'Etiology'</a>.)</p><p>Anterior uveitis typically causes pain and redness primarily at the limbus (junction between cornea and sclera); posterior or intermediate uveitis are more likely to be painless but more often associated with floaters. Visual loss may occur with anterior, intermediate, or posterior involvement. </p><p>A consensus conference has identified seven signs suggestive of intraocular sarcoidosis [<a href="#rid24">24,25</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Mutton-fat keratic precipitates (KPs)/small granulomatous KPs and/or iris nodules (Koeppe/Busacca)  (<a class="graphic graphic_picture graphicRef93503" href="/z/d/graphic/93503.html" rel="external">picture 10</a>) are a manifestation of lymphocytes in the anterior chamber of the eye (anterior uveitis). The floating lymphocytes form gray-white clumps that have the appearance of mutton fat under slit lamp examination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Trabecular meshwork nodules and/or tent-shaped peripheral anterior synechiae are seen in anterior uveitis. Patients complain of periocular pain and photophobia, but vision is often normal. The synechiae, or attachment, of the iris to the anterior surface of the lens or posterior surface of the cornea can cause an irregular pupil  (<a class="graphic graphic_picture graphicRef93504" href="/z/d/graphic/93504.html" rel="external">picture 11</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitreous opacities displaying snowballs/strings of pearls are a manifestation of intermediate uveitis, also known as pars planitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple chorioretinal peripheral lesions (active and/or atrophic).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nodular and/or segmental periphlebitis (with or without candlewax drippings)  (<a class="graphic graphic_picture graphicRef73985" href="/z/d/graphic/73985.html" rel="external">picture 12</a> and <a class="graphic graphic_picture graphicRef77545" href="/z/d/graphic/77545.html" rel="external">picture 13</a>) and/or retinal macroaneurysm in an inflamed eye are manifestations of retinal vasculitis (posterior uveitis) due to sarcoidosis. These lesions may be associated with retinal hemorrhage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Optic disc nodule(s)/granuloma(s) and/or solitary choroidal nodule.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bilaterality.</p><p></p><p>For patients without known sarcoidosis who present with suspected sarcoidosis uveitis, other causes of granulomatous uveitis (eg, tuberculosis, angiitis) should be excluded [<a href="#rid25">25</a>]. Based on consensus guidelines from the International Workshop on Ocular Sarcoidosis (IWOS), the certainty of a diagnosis of ocular sarcoidosis is based upon the combination of intraocular findings and systemic evidence of sarcoidosis [<a href="#rid25">25</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Uveitis compatible with sarcoidosis and an extraocular biopsy supporting sarcoidosis is felt to be diagnostic of ocular sarcoidosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A patient with two intraocular signs compatible with sarcoidosis <strong>and</strong> bilateral hilar adenopathy on chest imaging, but without a confirmatory biopsy, is presumed to have ocular sarcoidosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When a patient has a combination of three signs of uveitis compatible with sarcoidosis (eg, mutton fat precipitates, anterior synechiae, vitreous "string of pearls") and two other investigations in other organ systems supporting sarcoidosis (eg, chest imaging and negative <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a>) the diagnosis of sarcoidosis is felt to be probable.</p><p></p><p>The IWOS statement also included elevated serum angiotensin-converting enzyme, elevated serum lysozyme, elevated CD4/CD8 ratio (&gt;3.5) in bronchoalveolar lavage fluid, and lymphopenia as evidence of sarcoidosis [<a href="#rid25">25</a>], but the accuracy of these biomarkers is not broadly accepted [<a href="#rid26">26</a>]. </p><p class="headingAnchor" id="H41251086"><span class="h3">Extraocular orbital sarcoidosis</span><span class="headingEndMark"> — </span>Sarcoidosis may affect extraocular orbital tissues, including the lacrimal glands, conjunctiva, extraocular muscles, and optic sheath; it may also present as a soft tissue orbital mass [<a href="#rid27">27</a>]. Xerostomia and keratoconjunctivitis sicca may also be seen, similar to the clinical manifestations of Sjögren's disease and IgG4-related systemic disease. (See  <a class="medical medical_review" href="/z/d/html/5607.html" rel="external">"Clinical manifestations of Sjögren's disease: Exocrine gland disease", section on 'Dry eye'</a>.)</p><p>In a case series of 20 patients with orbital sarcoidosis, the most common symptoms were a palpable mass and orbital swelling [<a href="#rid27">27</a>]. The most common findings on orbital computed tomography (CT) were lacrimal gland involvement and orbital masses. Conjunctival granulomas are seen in approximately 5 percent of patients and are often amenable to biopsy. However, conjunctival biopsy has a low yield unless there is a visible abnormality [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H2954809998"><span class="h3">Vision outcomes</span><span class="headingEndMark"> — </span>A retrospective study examined the long-term outcomes (≥3 years) in 83 patients with sarcoidosis uveitis [<a href="#rid28">28</a>]. At presentation, 31 patients had systemic sarcoidosis, while 52 did not; 4 developed extraocular disease in follow-up. Complete visual recovery occurred in 60 percent and best corrected visual acuity (BCVA) to &gt;20/50 was achieved in 89 percent. Two patients experienced unilateral visual loss with BCVA ≤20/200, but no patient had bilateral severe visual loss. Chronic macular edema and persistent ocular inflammation were predictors of poor visual outcome.</p><p>Secondary glaucoma, cataract formation, and impaired vision are potential late complications of sarcoidosis that may be due to either the underlying disease or chronic glucocorticoid therapy. </p><p class="headingAnchor" id="H4231853957"><span class="h2">Neurologic</span><span class="headingEndMark"> — </span>Approximately 5 to 10 percent of patients with sarcoidosis have neurologic involvement, which can occasionally be the presenting symptom. Manifestations of central nervous system disease (eg, focal neurologic disorders, seizures, hypopituitarism, headache, granulomatous meningitis) usually occur early, while peripheral nerve involvement is characteristically seen in the later stages. (See  <a class="medical medical_review" href="/z/d/html/4834.html" rel="external">"Neurologic sarcoidosis"</a>.)</p><p>Fatigue is a common, nonspecific symptom in patients with sarcoidosis, occurring in up to 80 percent of patients [<a href="#rid29">29</a>]. The level of fatigue appears to be associated with the presence of extrapulmonary sarcoidosis (ie, those with extrapulmonary disease have higher levels of fatigue than those with only pulmonary sarcoidosis) [<a href="#rid30">30</a>]. A separate study found higher resting energy expenditure and increased C-reactive protein levels in the subset of patients with sarcoidosis who have fatigue [<a href="#rid31">31</a>]. Thus, fatigue likely reflects inflammation and metabolic derangements rather than neurologic involvement.</p><p>The clinical manifestations, diagnosis, and management of neurologic sarcoidosis are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/4834.html" rel="external">"Neurologic sarcoidosis"</a>.)</p><p class="headingAnchor" id="H569691785"><span class="h2">Endocrine and reproductive</span><span class="headingEndMark"> — </span>The most common endocrine manifestations of sarcoidosis include hypothalamic/pituitary involvement (due to basilar granulomatous meningitis) and infiltration of the thyroid.</p><p>Sarcoidosis involvement of the anterior pituitary can result in deficiency of adrenocorticotropic hormone, thyroid-stimulating hormone, follicle-stimulating hormone, luteinizing hormone, and insulin-like growth factor 1, along with elevated prolactin [<a href="#rid32">32,33</a>]. Presentations include diabetes insipidus, hypothalamic hypopituitarism, amenorrhea-galactorrhea, hypogonadotropic hypogonadism, and secondary hypothyroidism. In addition to endocrinologic evaluation, imaging with magnetic resonance imaging (MRI) to look for meningeal enhancement may be helpful diagnostically. (See  <a class="medical medical_review" href="/z/d/html/2381.html" rel="external">"Evaluation of patients with polyuria"</a> and  <a class="medical medical_review" href="/z/d/html/6637.html" rel="external">"Clinical manifestations of hypopituitarism", section on 'Hormone deficiencies'</a> and  <a class="medical medical_review" href="/z/d/html/6636.html" rel="external">"Causes of hypopituitarism", section on 'Infiltrative lesions'</a> and  <a class="medical medical_review" href="/z/d/html/6639.html" rel="external">"Diagnostic testing for hypopituitarism"</a> and  <a class="medical medical_review" href="/z/d/html/4834.html" rel="external">"Neurologic sarcoidosis", section on 'Diagnostic approach'</a>.)</p><p>Sarcoidosis can cause diffuse goiter or, rarely, a solitary thyroid nodule [<a href="#rid34">34,35</a>]. Almost all patients are euthyroid, although cases of clinical hypothyroidism caused by diffuse replacement of thyroid tissue have been reported [<a href="#rid36">36,37</a>]. (See  <a class="medical medical_review" href="/z/d/html/7861.html" rel="external">"Infiltrative thyroid disease"</a>.)</p><p>In the absence of significant cardiopulmonary compromise or endocrine disruption, systemic sarcoidosis does not affect fertility. Ongoing disease likewise does not increase the incidence of fetal or obstetrical complications [<a href="#rid38">38</a>]. </p><p>Sarcoidosis rarely involves the female genital tract. Case reports have described sarcoidosis of the endometrium, ovary, and uterine fibroids detected during the evaluation and treatment of menometrorrhagia or pelvic masses [<a href="#rid39">39-41</a>]. </p><p>Sarcoidosis can involve the testes, where it must be differentiated from testicular cancer and tuberculosis [<a href="#rid42">42</a>]. Recurrent epididymitis due to sarcoidosis rarely can occur [<a href="#rid36">36,43</a>].</p><p class="headingAnchor" id="H1881897074"><span class="h2">Parotid and salivary glands</span><span class="headingEndMark"> — </span>Painless swelling of the salivary and parotid glands occurs in approximately 5 percent of patients with sarcoidosis  (<a class="graphic graphic_table graphicRef76046" href="/z/d/graphic/76046.html" rel="external">table 1</a>) [<a href="#rid19">19,44,45</a>]. Severe parotid swelling can lead to facial nerve palsy due to direct compression of the cranial nerve. The combination of anterior uveitis, parotid gland enlargement, facial nerve palsy, and fever is referred to as uveoparotid fever or Heerfordt's syndrome, an uncommon but pathognomonic presentation of sarcoidosis. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Common extrapulmonary findings and pathognomonic syndromes'</a> and  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Pathognomonic presentations'</a>.)</p><p class="headingAnchor" id="H3585094975"><span class="h2">Lymphatic system</span><span class="headingEndMark"> — </span>Involvement of the lymphatic system is common in sarcoidosis and can manifest as:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphadenopathy</strong> – Peripheral lymphadenopathy is present in up to 40 percent of patients. Hilar and/or paratracheal mediastinal adenopathy are seen on imaging studies in up to 90 percent [<a href="#rid46">46</a>]; isolated anterior and posterior mediastinal adenopathy are uncommon in sarcoidosis [<a href="#rid47">47</a>]. Approximately 30 percent of patients with sarcoidosis have intra-abdominal lymphadenopathy (two nodes &gt;1 cm diameter on short axis) on abdominal CT scans [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Splenic enlargement</strong> – Approximately 6 percent of patients have splenomegaly on physical examination [<a href="#rid49">49</a>]. Radiographic cohorts vary in the recorded incidence of splenomegaly from 33 to nearly 80 percent [<a href="#rid48">48,50-52</a>]. In one cohort of 49 patients with complete splenic imaging, the greatest splenic dimension was ≥14 cm in 16 (33 percent) and ≥18 cm in 3 (6 percent) [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Splenic nodules</strong> – Splenic granulomas are found at autopsy in 50 percent of patients with sarcoidosis [<a href="#rid52">52</a>] but are often too small to visualize on imaging. Hypodense splenic nodules are seen on CT in approximately 15 percent [<a href="#rid51">51</a>]. In the absence of malignancy or known systemic infection, splenic nodules in a patient with systemic sarcoidosis almost always indicate splenic involvement. </p><p></p><p>Extrathoracic lymphadenopathy rarely results in additional symptoms. However, hypersplenism due to sarcoidosis can contribute to anemia, leukopenia, and thrombocytopenia [<a href="#rid53">53,54</a>]. Systemic anti-inflammatory therapy generally improves the cytopenias, although splenic nodules and splenomegaly may persist. Splenic enlargement may also cause left upper quadrant discomfort or early satiety. </p><p class="headingAnchor" id="H780156866"><span class="h2">Bone marrow</span><span class="headingEndMark"> — </span>In a large United States-based cohort, bone marrow involvement of sarcoidosis was approximately 4 percent  (<a class="graphic graphic_table graphicRef76046" href="/z/d/graphic/76046.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]; however, incidence has varied greatly depending on the population studied [<a href="#rid5">5,55</a>]. In one study of 50 patients evaluated with bone marrow biopsy irrespective of symptoms, 5 patients (10 percent) demonstrated granulomas on bone marrow biopsy; these cases represented 27 percent of those with anemia [<a href="#rid56">56</a>]. Anemia in sarcoidosis may also be caused by iron deficiency or anemia of chronic disease without bone marrow involvement. Leukopenia and thrombocytopenia may be seen with bone marrow infiltration, splenic involvement, or compartmentalization of white blood cells in other organ sites. (See <a class="local">'Lymphatic system'</a> above.)</p><p>In addition to the presence of cytopenias, bone marrow involvement may be suspected based on diffuse increased uptake of axial and peripheral bone marrow on 18-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET) imaging [<a href="#rid57">57</a>].</p><p>Cytopenias are uncommonly the deciding factor driving treatment decisions; however, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> may be a less preferred steroid-sparing agent in such patients due to its known marrow toxicity.</p><p class="headingAnchor" id="H18586383"><span class="h2">Upper respiratory tract</span><span class="headingEndMark"> — </span>Sarcoidosis of the upper respiratory tract (SURT) may involve the larynx, pharynx, nares, and/or sinuses; it should be suspected in all patients with systemic sarcoidosis and upper respiratory tract symptoms [<a href="#rid58">58-68</a>]. In general, SURT is challenging to treat and its presence portends a chronic, bothersome course for most patients.</p><p>The most frequent head and neck manifestation of sarcoidosis is cervical lymphadenopathy [<a href="#rid69">69</a>]. (See <a class="local">'Lymphatic system'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laryngeal sarcoidosis</strong> – Laryngeal involvement typically affects the supraglottis, less commonly the subglottis, and true vocal fold involvement is rare [<a href="#rid70">70</a>]. Presenting symptoms include dysphagia, dyspnea, cough, and hoarseness [<a href="#rid71">71,72</a>]. The diagnosis is made by direct visualization and biopsy. Treatment may include systemic or lesional immunosuppressive agents, or laser excision with <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">mitomycin</a> (also known as mitomycin-C) application [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nasal and sinus sarcoidosis</strong> – While sinonasal sarcoidosis occurs in approximately 1 percent of patients with sarcoidosis overall, involvement of the paranasal sinuses is common among patients with intranasal sarcoidosis [<a href="#rid59">59,73</a>]. (See  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis", section on 'Consider evaluation for systemic diseases'</a>.)</p><p></p><p class="bulletIndent1">In a case series of 36 patients with rhinosinusitis due to sarcoidosis, the most common symptoms and signs were nasal obstruction (86 percent), nasal crusting (47 percent), and anosmia (44 percent) [<a href="#rid65">65</a>]. Epistaxis and nasal polyposis were present in approximately 25 percent. The coexistence of facial lupus pernio and rhinosinusitis due to sarcoidosis has been variably reported [<a href="#rid64">64,65,74</a>]. </p><p></p><p class="bulletIndent1">On endoscopic examination, mucosal hypertrophy is common and two main patterns are seen [<a href="#rid65">65</a>]. Among patients without crusting and epistaxis, small discrete nodules (sometimes called granulations) may be visible on the inferior turbinates and/or septum. In contrast, patients who complain of crusting and epistaxis typically have the appearance of atrophic rhinitis with focal areas of hemorrhage and diffuse crusting of dried blood. These features can also be observed together [<a href="#rid64">64</a>]. </p><p></p><p class="bulletIndent1">Biopsy of the nasal mucosa is typically obtained when sarcoidosis is suspected based on the presence of mucosal nodules, when the diagnosis of sarcoidosis is unclear and the nasal mucosa is an accessible location for a biopsy, or when endoscopic sinus surgery is performed. Depending on the patient's history, examination for fungus, acid-fast mycobacteria, spirochetes, or vasculitis may be helpful. Due to the small number of patients in case series, the exact yield of nasal mucosal biopsy is not known, but at least one series found noncaseating granulomata in all of the patients who underwent biopsy. The differential diagnosis includes granulomatosis with polyangiitis, leprosy, and syphilis.</p><p></p><p class="bulletIndent1">Sinonasal sarcoidosis is typically treated like other causes of chronic rhinosinusitis. Regular nasal irrigation with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> solutions and instillation of intranasal glucocorticoids are the cornerstone of therapy. (See  <a class="medical medical_review" href="/z/d/html/121194.html" rel="external">"Chronic rhinosinusitis without nasal polyposis: Management and prognosis"</a>.)</p><p></p><p class="bulletIndent1">Systemic glucocorticoids and other immunosuppressive agents may occasionally be needed for severe disease, after exclusion of infection. Surgery should be avoided except in severe cases, due to the tendency for SURT to recur or even worsen after surgery.</p><p></p><p class="bulletIndent1">For patients with atrophic rhinitis due to longstanding nasal sarcoidosis, the main treatment is nasal lavage with warmed isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> at least twice daily  (<a class="graphic graphic_table graphicRef78832" href="/z/d/graphic/78832.html" rel="external">table 2</a>). Intranasal lubricants and/or glucocorticoids may also be helpful. (See  <a class="medical medical_review" href="/z/d/html/7531.html" rel="external">"Atrophic rhinosinusitis", section on 'Management'</a>.)</p><p></p><p class="headingAnchor" id="H341454170"><span class="h2">Cardiovascular</span><span class="headingEndMark"> — </span>Cardiac sarcoidosis can be a benign, incidentally discovered condition or a life-threatening disorder causing sudden death [<a href="#rid75">75</a>]. The frequency of myocardial involvement is unclear; small registries suggest a prevalence of 5 percent in patients with systemic sarcoidosis, while autopsy studies suggest subclinical cardiac involvement in 25 to 70 percent. (See  <a class="medical medical_review" href="/z/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis"</a>.) </p><p>The range of sarcoidosis involvement of the heart includes heart block (due to involvement of the conducting system), other arrhythmias, heart failure, valvular dysfunction, simulated infarction, and pericardial disease. Patients may be asymptomatic or may report palpitations, syncope, or dizziness. Clinically significant cardiac sarcoidosis is rare in subjects without symptoms and with a normal electrocardiogram (ECG). Patients with suspected cardiac involvement based on cardiac symptoms or ECG should be referred to a cardiologist and receive cardiac imaging, typically cardiac MRI. (See  <a class="medical medical_review" href="/z/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis"</a>.)</p><p>Treatment of clinically significant cardiac sarcoidosis may involve immunosuppressive therapy, cardiac pacemaker or implantable cardioverter-defibrillator placement, and/or standard therapies for heart failure. (See  <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis"</a>.)</p><p>Pulmonary hypertension is a life-threatening complication of sarcoidosis that manifests clinically with progressive exertional dyspnea and hypoxemia. Although typically a result of advanced lung fibrosis and hypoxemia, pulmonary hypertension may also arise from granulomatous inflammation in the pulmonary vascular tree or complications of cardiac sarcoidosis. The evaluation and management of pulmonary hypertension due to sarcoidosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/132051.html" rel="external">"Sarcoidosis-associated pulmonary hypertension: Diagnostic evaluation in adults"</a> and  <a class="medical medical_review" href="/z/d/html/138414.html" rel="external">"Sarcoidosis-associated pulmonary hypertension: Treatment and prognosis in adults"</a>.)</p><p class="headingAnchor" id="H1494527829"><span class="h2">Gastrointestinal and hepatic</span><span class="headingEndMark"> — </span>Clinically recognizable gastrointestinal disease occurs in 0.1 to 0.9 percent of patients with sarcoidosis, although the incidence of subclinical involvement may be much higher. The stomach is the most involved portion of the gastrointestinal tract, but sarcoidosis of the esophagus, appendix, colon, and rectum has also been described. Sarcoidosis can also involve pancreas and, rarely, the small bowel or peritoneum. Clinical manifestations, diagnosis, and management of these conditions is discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/4317.html" rel="external">"Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis"</a>.)</p><p>Liver involvement occurs in most patients with sarcoidosis but is frequently asymptomatic, with only 5 to 15 percent of patients developing abdominal pain, pruritus, or clinically significant hepatomegaly. For patients with sarcoidosis who have neither hepatic symptoms nor established hepatic sarcoidosis, consensus guidelines from the ATS suggest baseline serum alkaline phosphatase testing to screen for hepatic sarcoidosis [<a href="#rid14">14</a>]. Liver biopsy may sometimes be needed for patients with moderate or severe liver test abnormalities (eg, more than three times the upper limit of normal) to verify the diagnosis and determine severity of hepatic disease. (See  <a class="medical medical_review" href="/z/d/html/4317.html" rel="external">"Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis", section on 'Hepatic'</a>.)</p><p class="headingAnchor" id="H3779737868"><span class="h2">Renal and electrolyte</span><span class="headingEndMark"> — </span>Disorders related to calcium metabolism are the most common renal and electrolyte abnormalities observed among patients with sarcoidosis. Manifestations of abnormal calcium metabolism include increased intestinal calcium absorption, hypercalciuria (which occurs in up to 20 percent of cases), hypercalcemia (which occurs in 5 to 10 percent), nephrocalcinosis, and nephrolithiasis. If untreated, renal calcium deposition can lead to chronic renal failure and end-stage kidney disease. (See  <a class="medical medical_review" href="/z/d/html/841.html" rel="external">"Hypercalcemia in granulomatous diseases"</a> and  <a class="medical medical_review" href="/z/d/html/7186.html" rel="external">"Kidney disease in sarcoidosis", section on 'Nephrocalcinosis'</a>.)</p><p>Sarcoid interstitial nephritis is more commonly found on the initial presentation of sarcoidosis, rather than among patients with longstanding disease. The diagnosis is suggested by the combination of an elevated creatinine and bland urinary sediment in a patient with known or likely sarcoidosis. (See  <a class="medical medical_review" href="/z/d/html/7186.html" rel="external">"Kidney disease in sarcoidosis", section on 'Tubulointerstitial nephritis'</a>.)</p><p>Other renal complications of sarcoidosis include membranous nephropathy, a proliferative or crescentic glomerulonephritis, focal segmental glomerulosclerosis, polyuria (due to nephrogenic and/or central diabetes insipidus), hypertension, and a variety of tubular defects. (See  <a class="medical medical_review" href="/z/d/html/7186.html" rel="external">"Kidney disease in sarcoidosis"</a>.)</p><p class="headingAnchor" id="H18586395"><span class="h2">Musculoskeletal</span><span class="headingEndMark"> — </span>Musculoskeletal system involvement may occur in up to 10 percent of patients with sarcoidosis, usually as asymptomatic osseous involvement; other musculoskeletal manifestations occur in 1 to 2 percent of cases. Musculoskeletal sarcoidosis is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5583.html" rel="external">"Sarcoid arthropathy"</a> and  <a class="medical medical_review" href="/z/d/html/5586.html" rel="external">"Sarcoid myopathy"</a>.)</p><p>Common manifestations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute polyarthritis (especially symmetric involvement of the ankle joints), usually in association with EN and occasionally with acute uveitis. The swelling usually occurs in the soft tissue around joints, causing a periarthritis rather than a true arthritis [<a href="#rid76">76</a>]. Acute sarcoid arthritis may be present in isolation or in association with other features of Löfgren syndrome. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Common extrapulmonary findings and pathognomonic syndromes'</a> and  <a class="medical medical_review" href="/z/d/html/5612.html" rel="external">"Erythema nodosum"</a> and  <a class="medical medical_review" href="/z/d/html/5583.html" rel="external">"Sarcoid arthropathy", section on 'Acute arthritis and Lofgren syndrome'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic arthritis with periosteal bone resorption. Radiographically, this may appear as cysts, which can mimic rheumatoid disease  (<a class="graphic graphic_diagnosticimage graphicRef70918" href="/z/d/graphic/70918.html" rel="external">image 1</a>). This form of arthritis is usually associated with a chronic protracted course. No correlation exists between the osseous lesions and the plasma calcium concentration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diffuse granulomatous myositis. An uncommon complication of sarcoidosis, it indicates progressive disease and is associated with a poor prognosis.</p><p></p><p class="headingAnchor" id="H4226925196"><span class="h1">ONGOING MONITORING</span><span class="headingEndMark"> — </span>Appreciation of the spectrum of extrapulmonary sarcoidosis is essential in the ongoing management of patients with known sarcoidosis. Routine monitoring of sarcoidosis includes evaluation for the types of extrapulmonary involvement that can lead to organ or life-threatening disease. This monitoring begins with questions on new symptoms (eg, visual changes, palpitations, presyncope/syncope), followed by appropriate additional evaluation and management. For asymptomatic patients, our authors suggest variable monitoring schedules based on disease activity  (<a class="graphic graphic_table graphicRef67386" href="/z/d/graphic/67386.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Ongoing monitoring'</a>.)</p><p class="headingAnchor" id="H1178622607"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116637.html" rel="external">"Society guideline links: Sarcoidosis"</a>.)</p><p class="headingAnchor" id="H285898066"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of extrapulmonary disease</strong> – Sarcoidosis can involve all organ systems  (<a class="graphic graphic_table graphicRef76046" href="/z/d/graphic/76046.html" rel="external">table 1</a>). The most common sites of extrapulmonary disease include the skin, eyes, reticuloendothelial system, musculoskeletal system, exocrine glands, heart, kidney, and central nervous system. Extrapulmonary manifestations vary on the basis of sex, age at presentation, and ethnicity  (<a class="graphic graphic_figure graphicRef77449" href="/z/d/graphic/77449.html" rel="external">figure 1</a>). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extrapulmonary disease in initial diagnosis</strong> – In addition to clinical evaluation, baseline testing for occult extrapulmonary disease is recommended as part of the initial work-up of sarcoidosis. Löfgren syndrome (erythema nodosum [EN], hilar adenopathy, migratory polyarthralgia, and fever) and Heerfordt's syndrome (uveoparotid fever) are characteristic syndromes that allow for a clinical diagnosis of sarcoidosis. Occasionally, cumulative probable manifestations in multiple organ systems may also allow for a presumptive diagnosis. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Common extrapulmonary findings and pathognomonic syndromes'</a> and  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Testing for occult extrapulmonary disease'</a> and  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Invasive diagnostic testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extrapulmonary manifestations, by organ system</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cutaneous</strong> – Approximately 25 percent of patients with sarcoidosis demonstrate skin findings. (See <a class="local">'Cutaneous'</a> above and  <a class="medical medical_review" href="/z/d/html/13762.html" rel="external">"Cutaneous manifestations of sarcoidosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ocular</strong> – Sarcoidosis can cause anterior, intermediate, and posterior uveitis, as well as retinal periphlebitis. Extraocular involvement can affect the lacrimal glands, conjunctiva, and ocular muscles. All patients with suspected sarcoidosis should undergo baseline ophthalmologic examination and should be monitored for changes in vision, eye pain, and photophobia. (See <a class="local">'Ocular'</a> above and  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Ongoing monitoring'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nervous system</strong> – Neurologic involvement occurs in approximately 5 percent of patients with sarcoidosis and can be the presenting feature. Common syndromes include cranial mononeuropathy, neuroendocrine dysfunction, a focal or multifocal encephalopathy, myelopathy, hydrocephalus, aseptic meningitis, and peripheral neuropathy. (See <a class="local">'Neurologic'</a> above and  <a class="medical medical_review" href="/z/d/html/4834.html" rel="external">"Neurologic sarcoidosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endocrine and reproductive</strong> – Endocrine manifestations of sarcoidosis include hypothalamic involvement and infiltration of the thyroid. Sarcoidosis can occasionally be found in reproductive organs. (See <a class="local">'Endocrine and reproductive'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Parotid and salivary glands</strong> – Painless swelling of the salivary and parotid glands occurs in approximately 5 percent of patients. (See <a class="local">'Parotid and salivary glands'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lymphatic system</strong> – Lymphadenopathy is very common in sarcoidosis, with hilar, peripheral, and intra-abdominal lymphadenopathy seen in approximately 90, 40, and 30 percent of patients, respectively. Splenic involvement may result in splenomegaly or hypoattenuating splenic lesions; splenic sarcoidosis is usually subclinical but may contribute to leukopenia and thrombocytopenia. (See <a class="local">'Lymphatic system'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Upper respiratory tract</strong> – Sarcoidosis can involve the larynx, pharynx, nares, and/or sinuses and should be suspected in those with upper respiratory tract symptoms. (See <a class="local">'Upper respiratory tract'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiovascular</strong> – The range of sarcoid involvement of the heart includes heart block and arrhythmias (due to involvement of the conducting system), heart failure, valvular dysfunction, and pericardial disease. The initial evaluation of all patients with sarcoidosis should include an electrocardiogram (ECG). (See <a class="local">'Cardiovascular'</a> above and  <a class="medical medical_review" href="/z/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis"</a> and  <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastrointestinal and hepatic</strong> – Hepatic involvement is common but rarely symptomatic; surveillance for right upper quadrant pain, pruritus, and elevated alkaline phosphatase is appropriate. Clinically recognizable gastrointestinal disease occurs in less than 1 percent of patients with sarcoidosis. (See <a class="local">'Gastrointestinal and hepatic'</a> above and  <a class="medical medical_review" href="/z/d/html/4317.html" rel="external">"Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Renal and electrolyte</strong> – Abnormalities related to calcium metabolism are common in sarcoidosis, so surveillance of serum calcium is recommended to prevent nephrocalcinosis and nephrolithiasis. Other relatively common renal complications of sarcoidosis include interstitial nephritis and membranous nephropathy. (See <a class="local">'Renal and electrolyte'</a> above and  <a class="medical medical_review" href="/z/d/html/7186.html" rel="external">"Kidney disease in sarcoidosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Musculoskeletal</strong> – Acute periarthritis due to sarcoidosis typically causes symmetric involvement of the ankle joints but may involve other joints. Chronic erosive arthritis and granulomatous myositis may also occur later in the disease course. (See <a class="local">'Musculoskeletal'</a> above and  <a class="medical medical_review" href="/z/d/html/5583.html" rel="external">"Sarcoid arthropathy"</a> and  <a class="medical medical_review" href="/z/d/html/5586.html" rel="external">"Sarcoid myopathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine monitoring</strong> – Appreciation of the spectrum of extrapulmonary sarcoidosis is essential in the ongoing management of patients with known sarcoidosis. Routine monitoring includes clinical and laboratory evaluation for the types of extrapulmonary involvement that can lead to organ or life-threatening disease  (<a class="graphic graphic_table graphicRef67386" href="/z/d/graphic/67386.html" rel="external">table 3</a>). (See <a class="local">'Ongoing Monitoring'</a> above and  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Ongoing monitoring'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164:1885.</a></li><li><a class="nounderline abstract_t">Rizzato G, Tinelli C. Unusual presentation of sarcoidosis. Respiration 2005; 72:3.</a></li><li><a class="nounderline abstract_t">Rizzato G, Palmieri G, Agrati AM, Zanussi C. The organ-specific extrapulmonary presentation of sarcoidosis: a frequent occurrence but a challenge to an early diagnosis. A 3-year-long prospective observational study. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:119.</a></li><li><a class="nounderline abstract_t">Judson MA, Thompson BW, Rabin DL, et al. The diagnostic pathway to sarcoidosis. Chest 2003; 123:406.</a></li><li><a class="nounderline abstract_t">Mañá J, Rubio-Rivas M, Villalba N, et al. Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: Cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain. Medicine (Baltimore) 2017; 96:e7595.</a></li><li><a class="nounderline abstract_t">James WE, Koutroumpakis E, Saha B, et al. Clinical Features of Extrapulmonary Sarcoidosis Without Lung Involvement. Chest 2018; 154:349.</a></li><li><a class="nounderline abstract_t">Li CW, Tao RJ, Zou DF, et al. Pulmonary sarcoidosis with and without extrapulmonary involvement: a cross-sectional and observational study in China. BMJ Open 2018; 8:e018865.</a></li><li><a class="nounderline abstract_t">Valeyre D, Jeny F, Rotenberg C, et al. How to Tackle the Diagnosis and Treatment in the Diverse Scenarios of Extrapulmonary Sarcoidosis. Adv Ther 2021; 38:4605.</a></li><li><a class="nounderline abstract_t">Ungprasert P, Carmona EM, Utz JP, et al. Epidemiology of Sarcoidosis 1946-2013: A Population-Based Study. Mayo Clin Proc 2016; 91:183.</a></li><li><a class="nounderline abstract_t">Judson MA. The Clinical Features of Sarcoidosis: A Comprehensive Review. Clin Rev Allergy Immunol 2015; 49:63.</a></li><li><a class="nounderline abstract_t">Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29:119.</a></li><li><a class="nounderline abstract_t">Lhote R, Annesi-Maesano I, Nunes H, et al. Clinical phenotypes of extrapulmonary sarcoidosis: an analysis of a French, multi-ethnic, multicentre cohort. Eur Respir J 2021; 57.</a></li><li><a class="nounderline abstract_t">Schupp JC, Freitag-Wolf S, Bargagli E, et al. Phenotypes of organ involvement in sarcoidosis. Eur Respir J 2018; 51.</a></li><li><a class="nounderline abstract_t">Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020; 201:e26.</a></li><li><a class="nounderline abstract_t">Jamilloux Y, Kodjikian L, Broussolle C, Sève P. Sarcoidosis and uveitis. Autoimmun Rev 2014; 13:840.</a></li><li><a class="nounderline abstract_t">Patel S. Ocular sarcoidosis. Int Ophthalmol Clin 2015; 55:15.</a></li><li><a class="nounderline abstract_t">Evans M, Sharma O, LaBree L, et al. Differences in clinical findings between Caucasians and African Americans with biopsy-proven sarcoidosis. Ophthalmology 2007; 114:325.</a></li><li><a class="nounderline abstract_t">Birnbaum AD, French DD, Mirsaeidi M, Wehrli S. Sarcoidosis in the national veteran population: association of ocular inflammation and mortality. Ophthalmology 2015; 122:934.</a></li><li><a class="nounderline abstract_t">James DG, Sharma OP. Parotid gland sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17:27.</a></li><li><a class="nounderline abstract_t">Petropoulos IK, Zuber JP, Guex-Crosier Y. Heerfordt syndrome with unilateral facial nerve palsy: a rare presentation of sarcoidosis. Klin Monbl Augenheilkd 2008; 225:453.</a></li><li><a class="nounderline abstract_t">Herbort CP, Rao NA, Mochizuki M, members of Scientific Committee of First International Workshop on Ocular Sarcoidosis. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm 2009; 17:160.</a></li><li><a class="nounderline abstract_t">Korkmaz Ekren P, Mogulkoc N, Toreyin ZN, et al. Conjunctival Biopsy as a First Choice to Confirm a Diagnosis of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33:196.</a></li><li><a class="nounderline abstract_t">Ma SP, Rogers SL, Hall AJ, et al. Sarcoidosis-related Uveitis: Clinical Presentation, Disease Course, and Rates of Systemic Disease Progression After Uveitis Diagnosis. Am J Ophthalmol 2019; 198:30.</a></li><li class="breakAll">Ohara K, Judson MA, Baughman RP. Clincial aspects of ocular sarcoidosis. In: European Respiratory Monograph, ERS Journals, Ltd, 2005. p.188.</li><li><a class="nounderline abstract_t">Mochizuki M, Smith JR, Takase H, et al. Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis. Br J Ophthalmol 2019; 103:1418.</a></li><li class="breakAll">Bristish Thoracic Society. BTS Clinical Statement on Pulmonary Sarcoidosis: 2019. https://brit-thoracic.org.uk/quality-improvement/clinical-statements/sarcoidosis/ (Accessed on February 19, 2020).</li><li><a class="nounderline abstract_t">Mavrikakis I, Rootman J. Diverse clinical presentations of orbital sarcoid. Am J Ophthalmol 2007; 144:769.</a></li><li><a class="nounderline abstract_t">Rochepeau C, Jamilloux Y, Kerever S, et al. Long-term visual and systemic prognoses of 83 cases of biopsy-proven sarcoid uveitis. Br J Ophthalmol 2017; 101:856.</a></li><li><a class="nounderline abstract_t">de Kleijn WP, De Vries J, Lower EE, et al. Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med 2009; 15:499.</a></li><li><a class="nounderline abstract_t">Fleischer M, Hinz A, Brähler E, et al. Factors associated with fatigue in sarcoidosis. Respir Care 2014; 59:1086.</a></li><li><a class="nounderline abstract_t">Drent M, Wirnsberger RM, de Vries J, et al. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J 1999; 13:718.</a></li><li><a class="nounderline abstract_t">Aghajanova L, Jaffe RB, Herndon CN. Infiltrative neurosarcoidosis presenting as secondary amenorrhea: case report and review of the literature. Obstet Gynecol Surv 2013; 68:482.</a></li><li><a class="nounderline abstract_t">Murialdo G, Tamagno G. Endocrine aspects of neurosarcoidosis. J Endocrinol Invest 2002; 25:650.</a></li><li><a class="nounderline abstract_t">Vailati A, Marena C, Aristia L, et al. Sarcoidosis of the thyroid: report of a case and a review of the literature. Sarcoidosis 1993; 10:66.</a></li><li><a class="nounderline abstract_t">Warshawsky ME, Shanies HM, Rozo A. Sarcoidosis involving the thyroid and pleura. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14:165.</a></li><li><a class="nounderline abstract_t">Porter N, Beynon HL, Randeva HS. Endocrine and reproductive manifestations of sarcoidosis. QJM 2003; 96:553.</a></li><li><a class="nounderline abstract_t">Bell NH. Endocrine complications of sarcoidosis. Endocrinol Metab Clin North Am 1991; 20:645.</a></li><li><a class="nounderline abstract_t">Selroos O. Sarcoidosis and pregnancy: a review with results of a retrospective survey. J Intern Med 1990; 227:221.</a></li><li><a class="nounderline abstract_t">Menzin AW, You TT, Deger RB, et al. Sarcoidosis in a uterine leiomyoma. Int J Gynaecol Obstet 1995; 48:79.</a></li><li><a class="nounderline abstract_t">DiCarlo FJ Jr, DiCarlo JP, Robboy SJ, Lyons MM. Sarcoidosis of the uterus. Arch Pathol Lab Med 1989; 113:941.</a></li><li><a class="nounderline abstract_t">Droessler J, Williams T, Haggstrom J, et al. A Periurethral Mass in a Female Patient With Sarcoidosis. Urology 2018; 114:18.</a></li><li><a class="nounderline abstract_t">Massarweh NN, Bhalani VK, Shaw KK, et al. Testicular presentation of sarcoidosis and organ preservation: case report and review of management strategies. Urology 2006; 67:200.</a></li><li><a class="nounderline abstract_t">Haas GP, Badalament R, Wonnell DM, Miles BJ. Testicular sarcoidosis: case report and review of the literature. J Urol 1986; 135:1254.</a></li><li><a class="nounderline abstract_t">O'Regan A, Berman JS. Sarcoidosis. Ann Intern Med 2012; 156:ITC5.</a></li><li><a class="nounderline abstract_t">Ungprasert P, Crowson CS, Matteson EL. Clinical Characteristics of Parotid Gland Sarcoidosis: A Population-Based Study. JAMA Otolaryngol Head Neck Surg 2016; 142:503.</a></li><li><a class="nounderline abstract_t">Müller NL, Kullnig P, Miller RR. The CT findings of pulmonary sarcoidosis: analysis of 25 patients. AJR Am J Roentgenol 1989; 152:1179.</a></li><li><a class="nounderline abstract_t">Vagal AS, Shipley R, Meyer CA. Radiological manifestations of sarcoidosis. Clin Dermatol 2007; 25:312.</a></li><li><a class="nounderline abstract_t">Warshauer DM, Lee JK. Imaging manifestations of abdominal sarcoidosis. AJR Am J Roentgenol 2004; 182:15.</a></li><li><a class="nounderline abstract_t">Salazar A, Mañá J, Corbella X, et al. Splenomegaly in sarcoidosis: a report of 16 cases. Sarcoidosis 1995; 12:131.</a></li><li><a class="nounderline abstract_t">Britt AR, Francis IR, Glazer GM, Ellis JH. Sarcoidosis: abdominal manifestations at CT. Radiology 1991; 178:91.</a></li><li><a class="nounderline abstract_t">Warshauer DM, Dumbleton SA, Molina PL, et al. Abdominal CT findings in sarcoidosis: radiologic and clinical correlation. Radiology 1994; 192:93.</a></li><li><a class="nounderline abstract_t">Webb AK, Mitchell DN, Bradstreet CM, Salsbury AJ. Splenomegaly and splenectomy in sarcoidosis. J Clin Pathol 1979; 32:1050.</a></li><li><a class="nounderline abstract_t">Sharma OP, Vucinic V, James DG. Splenectomy in sarcoidosis: indications, complications, and long-term follow-up. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:66.</a></li><li><a class="nounderline abstract_t">Madaule S, Lauque D, Sailler L, et al. [Splenomegaly in sarcoidosis: clinical features and outcome. Analysis of 17 cases]. Rev Med Interne 2004; 25:348.</a></li><li><a class="nounderline abstract_t">Carrillo-Pérez DL, Apodaca-Cháveza EI, Carrillo-Maravilla E, et al. Sarcoidosis: a single hospital-based study in a 24-year period. Rev Invest Clin 2015; 67:33.</a></li><li><a class="nounderline abstract_t">Yanardağ H, Pamuk GE, Karayel T, Demirci S. Bone marrow involvement in sarcoidosis: an analysis of 50 bone marrow samples. Haematologia (Budap) 2002; 32:419.</a></li><li><a class="nounderline abstract_t">Mostard RL, Prompers L, Weijers RE, et al. F-18 FDG PET/CT for detecting bone and bone marrow involvement in sarcoidosis patients. Clin Nucl Med 2012; 37:21.</a></li><li><a class="nounderline abstract_t">Fouty BW, Pomeranz M, Thigpen TP, Martin RJ. Dilatation of bronchial stenoses due to sarcoidosis using a flexible fiberoptic bronchoscope. Chest 1994; 106:677.</a></li><li><a class="nounderline abstract_t">Braun JJ, Gentine A, Pauli G. Sinonasal sarcoidosis: review and report of fifteen cases. Laryngoscope 2004; 114:1960.</a></li><li><a class="nounderline abstract_t">Long CM, Smith TL, Loehrl TA, et al. Sinonasal disease in patients with sarcoidosis. Am J Rhinol 2001; 15:211.</a></li><li><a class="nounderline abstract_t">Kay DJ, Har-El G. The role of endoscopic sinus surgery in chronic sinonasal sarcoidosis. Am J Rhinol 2001; 15:249.</a></li><li><a class="nounderline abstract_t">Rottoli P, Bargagli E, Chidichimo C, et al. Sarcoidosis with upper respiratory tract involvement. Respir Med 2006; 100:253.</a></li><li><a class="nounderline abstract_t">deShazo RD, O'Brien MM, Justice WK, Pitcock J. Diagnostic criteria for sarcoidosis of the sinuses. J Allergy Clin Immunol 1999; 103:789.</a></li><li><a class="nounderline abstract_t">Baughman RP, Lower EE, Tami T. Upper airway. 4: Sarcoidosis of the upper respiratory tract (SURT). Thorax 2010; 65:181.</a></li><li><a class="nounderline abstract_t">Reed J, deShazo RD, Houle TT, et al. Clinical features of sarcoid rhinosinusitis. Am J Med 2010; 123:856.</a></li><li><a class="nounderline abstract_t">Knopf A, Lahmer T, Chaker A, et al. Head and neck sarcoidosis, from wait and see to tumor necrosis factor alpha therapy: a pilot study. Head Neck 2013; 35:715.</a></li><li><a class="nounderline abstract_t">Kirsten AM, Watz H, Kirsten D. Sarcoidosis with involvement of the paranasal sinuses - a retrospective analysis of 12 biopsy-proven cases. BMC Pulm Med 2013; 13:59.</a></li><li><a class="nounderline abstract_t">Lawson W, Jiang N, Cheng J. Sinonasal sarcoidosis: A new system of classification acting as a guide to diagnosis and treatment. Am J Rhinol Allergy 2014; 28:317.</a></li><li><a class="nounderline abstract_t">Send T, Korsten P, Bertlich M, et al. Clinical features of sarcoidosis patients presenting with head and neck manifestations - a two-center retrospective study and proposal of a diagnostic algorithm for the otorhinolaryngologist. Acta Otolaryngol 2020; 140:144.</a></li><li><a class="nounderline abstract_t">McLaughlin RB, Spiegel JR, Selber J, et al. Laryngeal sarcoidosis presenting as an isolated submucosal vocal fold mass. J Voice 1999; 13:240.</a></li><li><a class="nounderline abstract_t">James JC, Simpson CB. Treatment of laryngeal sarcoidosis with CO2 laser and mitomycin-C. Otolaryngol Head Neck Surg 2004; 130:262.</a></li><li><a class="nounderline abstract_t">Ryu C, Herzog EL, Pan H, et al. Upper Airway Obstruction Requiring Emergent Tracheostomy Secondary to Laryngeal Sarcoidosis: A Case Report. Am J Case Rep 2017; 18:157.</a></li><li><a class="nounderline abstract_t">Send T, Tuleta I, Koppen T, et al. Sarcoidosis of the paranasal sinuses. Eur Arch Otorhinolaryngol 2019; 276:1969.</a></li><li><a class="nounderline abstract_t">Aubart FC, Ouayoun M, Brauner M, et al. Sinonasal involvement in sarcoidosis: a case-control study of 20 patients. Medicine (Baltimore) 2006; 85:365.</a></li><li><a class="nounderline abstract_t">Serei VD, Fyfe B. The Many Faces of Cardiac Sarcoidosis. Am J Clin Pathol 2020; 153:294.</a></li><li><a class="nounderline abstract_t">Kellner H, Späthling S, Herzer P. Ultrasound findings in Löfgren's syndrome: is ankle swelling caused by arthritis, tenosynovitis or periarthritis? J Rheumatol 1992; 19:38.</a></li></ol></div><div id="topicVersionRevision">Topic 91259 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11734441" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical characteristics of patients in a case control study of sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753626" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Unusual presentation of sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15281433" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The organ-specific extrapulmonary presentation of sarcoidosis: a frequent occurrence but a challenge to an early diagnosis. A 3-year-long prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576358" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The diagnostic pathway to sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28723801" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: Cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29453944" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical Features of Extrapulmonary Sarcoidosis Without Lung Involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29453299" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pulmonary sarcoidosis with and without extrapulmonary involvement: a cross-sectional and observational study in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34296400" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : How to Tackle the Diagnosis and Treatment in the Diverse Scenarios of Extrapulmonary Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26727158" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Epidemiology of Sarcoidosis 1946-2013: A Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25274450" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The Clinical Features of Sarcoidosis: A Comprehensive Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23461074" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33093118" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical phenotypes of extrapulmonary sarcoidosis: an analysis of a French, multi-ethnic, multicentre cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29371378" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Phenotypes of organ involvement in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32293205" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24704868" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Sarcoidosis and uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26035759" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Ocular sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17123620" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Differences in clinical findings between Caucasians and African Americans with biopsy-proven sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25687027" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Sarcoidosis in the national veteran population: association of ocular inflammation and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10746259" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Parotid gland sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18454397" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Heerfordt syndrome with unilateral facial nerve palsy: a rare presentation of sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19585358" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27758983" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Conjunctival Biopsy as a First Choice to Confirm a Diagnosis of Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30243930" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Sarcoidosis-related Uveitis: Clinical Presentation, Disease Course, and Rates of Systemic Disease Progression After Uveitis Diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30243930" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sarcoidosis-related Uveitis: Clinical Presentation, Disease Course, and Rates of Systemic Disease Progression After Uveitis Diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30798264" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30798264" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17869205" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Diverse clinical presentations of orbital sarcoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27888183" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-term visual and systemic prognoses of 83 cases of biopsy-proven sarcoid uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19458531" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fatigue in sarcoidosis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24255156" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Factors associated with fatigue in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10362029" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Association of fatigue with an acute phase response in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23942474" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Infiltrative neurosarcoidosis presenting as secondary amenorrhea: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12150344" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Endocrine aspects of neurosarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8134720" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Sarcoidosis of the thyroid: report of a case and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9306508" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Sarcoidosis involving the thyroid and pleura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12897340" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Endocrine and reproductive manifestations of sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1935922" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Endocrine complications of sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2324675" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Sarcoidosis and pregnancy: a review with results of a retrospective survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7698388" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sarcoidosis in a uterine leiomyoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2667499" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Sarcoidosis of the uterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29122626" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A Periurethral Mass in a Female Patient With Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16413374" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Testicular presentation of sarcoidosis and organ preservation: case report and review of management strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3712583" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Testicular sarcoidosis: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22547486" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26986899" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical Characteristics of Parotid Gland Sarcoidosis: A Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2718853" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The CT findings of pulmonary sarcoidosis: analysis of 25 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17560309" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Radiological manifestations of sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14684507" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Imaging manifestations of abdominal sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8532960" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Splenomegaly in sarcoidosis: a report of 16 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984330" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Sarcoidosis: abdominal manifestations at CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8208972" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Abdominal CT findings in sarcoidosis: radiologic and clinical correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/521496" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Splenomegaly and splenectomy in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12002389" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Splenectomy in sarcoidosis: indications, complications, and long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15110952" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : [Splenomegaly in sarcoidosis: clinical features and outcome. Analysis of 17 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25857582" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Sarcoidosis: a single hospital-based study in a 24-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12803116" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Bone marrow involvement in sarcoidosis: an analysis of 50 bone marrow samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22157023" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : F-18 FDG PET/CT for detecting bone and bone marrow involvement in sarcoidosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8082337" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Dilatation of bronchial stenoses due to sarcoidosis using a flexible fiberoptic bronchoscope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15510022" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Sinonasal sarcoidosis: review and report of fifteen cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11453511" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Sinonasal disease in patients with sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11554657" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The role of endoscopic sinus surgery in chronic sinonasal sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15932795" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Sarcoidosis with upper respiratory tract involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10329811" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Diagnostic criteria for sarcoidosis of the sinuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20147594" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Upper airway. 4: Sarcoidosis of the upper respiratory tract (SURT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20800155" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical features of sarcoid rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22730039" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Head and neck sarcoidosis, from wait and see to tumor necrosis factor alpha therapy: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24070015" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Sarcoidosis with involvement of the paranasal sinuses - a retrospective analysis of 12 biopsy-proven cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25197919" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Sinonasal sarcoidosis: A new system of classification acting as a guide to diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31825705" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Clinical features of sarcoidosis patients presenting with head and neck manifestations - a two-center retrospective study and proposal of a diagnostic algorithm for the otorhinolaryngologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10442754" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Laryngeal sarcoidosis presenting as an isolated submucosal vocal fold mass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14990925" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treatment of laryngeal sarcoidosis with CO2 laser and mitomycin-C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28190872" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Upper Airway Obstruction Requiring Emergent Tracheostomy Secondary to Laryngeal Sarcoidosis: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30900021" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Sarcoidosis of the paranasal sinuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17108780" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Sinonasal involvement in sarcoidosis: a case-control study of 20 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31769474" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The Many Faces of Cardiac Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1556697" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Ultrasound findings in Löfgren's syndrome: is ankle swelling caused by arthritis, tenosynovitis or periarthritis?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
